Please find attached the minutes from the Extraordinary General Meeting (EGM) of EXACT Therapeutics AS held on 24 July 2020. All resolutions were approved as proposed by the Board of Directors, including the 1:250 split of the company's shares and the appointment of EY as auditors.
For further queries, please contact:
Masha Stromme, Chair +47 93022509
Stig Jarle Pettersen, CFO +47 90960336
EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com